David Hodl
Head of Sales, Cell Therapy Custom and Configured Platforms • Invetech
David has over 23 years of experience in product commercialization and business development roles. Prior to joining Invetech David led the Cell Processing business unit of SynGen, commercializing equipment and single-use consumables for manufacturing cell-based therapies. He also spent eight years in a business development role with Becton Dickinson’s Corporate Innovation Center, focusing on commercialization of cell-based and next-generation sequencing technologies. David earned an MBA from North Carolina State University and a BA in biology from Linfield College
Also Speaking
Kimberly Goodspeed
Assistant Professor • University of Texas Southwestern Medical Center
31 October 2022
Brad Carlin
Senior Advisor, Statistics and Data Science • PharmaLex GmbH (Biopharma excellence)
26 October 2022
Also Speaking
Investor List
Take a look at some of the investors who attended Advanced Therapies Week 2023.
6 January 2023
